 |
Prospector
Profile
07.1255
|
| |
| Photomedex, Inc. |
NAICS |
334510 |
| 147 Keystone Drive
Montgomeryville, PA 18936 |
Description |
Laser Equipment Mfg. |
| (215) 619-3600 |
Employees |
192 |
| http://www.photomedex.com/ |
Revenue |
(mil) |
33.1890 |
| |
Income |
(mil) |
-7.4920 |
| |
Assets |
(mil) |
57.4810 |
| |
Liability |
(mil) |
13.3780 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Photomedex, Inc. reported a net loss of $1,835,958 on revenues of $9,318,720 for the three months ended June 30, 2007, compared to a net loss of $1,339,931 on revenues of $8,223,743 for the three months ended June 30, 2006. As of June 30, 2007, the Company has an accumulated deficit of $91,394,443. The Company's balance sheet also showed $57,002,547 in assets, including $16,917,808 in goodwill, $15,700,392 in liabilities and $41,302,155 in equity.
|
| |
|
Intellectual Property:
The patents in its Skin Care segment relate to use of copper peptide-based technology for a variety of healthcare applications, and to the composition of certain biologically active, synthesized compounds. The Company's strategy has been to apply for patent protection for certain compounds and their discovered uses that are believed to have potential commercial value in countries that offer significant market potential. As of March 15, 2007, the Company has more than 120 domestic and foreign issued patents, which serve to help protect the technology of its businesses in phototherapy, skin health and hair care, and surgical products and services. To the same purpose, it has 40 patent applications pending in the United States and abroad. The Company licensed certain proprietary technology in phototherapy to Komatsu, Ltd. in connection with its manufacture of semi-conductor lithography equipment, for which it is entitled to receive royalty fees. The Company has also licensed its copper peptide technology to Neutrogena, for which it currently receives royalties. [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The Company engages in the development, manufacture, and marketing of medical laser products and services in the United States and internationally.
|
| |
|
Officers:
Richard J. DePiano (Chair); Jeffrey F. O'Donnell (Pres., CEO & Dir.); Dennis M. McGrath (VP & CFO); Michael R. Stewart (EVP & COO); Alan R. Novak (Dir.); Warwick Alex Charlton (Dir.); Anthony J. Dimun (Dir.); David W. Anderson (Dir.); Wayne M. Withrow (Dir.)
|
| |
|
Auditor:
Amper Politziner & Mattia PC
|
| |
|
Securities:
Common Stock-Symbol PHMD; NasdaqGM;
62,874,707 common shares outstanding as of August 9, 2007.
|
| |
| |
| |
| return to main page |
|
|
